Diabetic Immunotherapy Advances with BCG: Metabolic and Immune Reprogramming
Denise L. Faustman, Shiho Hashiguchi, Miriam Davis, Willem Kuhtreiber · 2026
Read Diabetic Immunotherapy Advances with BCG: Metabolic and Immune Reprogramming by Denise L. Faustman, Shiho Hashiguchi, Miriam Davis, Willem Kuhtreiber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565049.txt.
Description
Denise Faustman and co-authors review, in 2026, an old tuberculosis vaccine being repurposed against autoimmune diabetes. The vaccine, BCG, has a century of safety data and decades of use in bladder cancer. Trials over fifteen years gave adults with longstanding type 1 diabetes repeated doses and tracked blood sugar.
Treated patients held near-normal levels of the standard sugar marker for at least eight years, without the pancreas recovering. The proposed mechanism is metabolic: the vaccine fixes a fuel-burning defect in immune cells, so they pull more sugar from the blood. The review extends the story to a slower adult form of the disease.
Catalog record
| CREATOR | Denise L. Faustman, Shiho Hashiguchi, Miriam Davis, Willem Kuhtreiber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |